Zacks Research Analysts Boost Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research lifted their Q2 2025 EPS estimates for shares of Teva Pharmaceutical Industries in a report issued on Wednesday, April 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.57 for the quarter, up from their prior forecast of $0.56. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.53 EPS and FY2026 earnings at $2.70 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The company had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion.

A number of other brokerages also recently commented on TEVA. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $12.00 to $19.00 in a research report on Monday, February 12th. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a research note on Friday, March 8th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Finally, The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.78.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $13.19 on Thursday. The firm has a 50-day moving average of $13.45 and a 200-day moving average of $11.21. Teva Pharmaceutical Industries has a one year low of $7.09 and a one year high of $14.47. The company has a market cap of $14.79 billion, a PE ratio of -28.06, a price-to-earnings-growth ratio of 1.57 and a beta of 1.05. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Teva Pharmaceutical Industries by 3.7% in the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock worth $391,081,000 after purchasing an additional 1,494,814 shares during the period. Phoenix Holdings Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 2.3% in the 3rd quarter. Phoenix Holdings Ltd. now owns 34,481,692 shares of the company’s stock worth $351,713,000 after purchasing an additional 778,282 shares during the period. Lingotto Investment Management LLP lifted its position in shares of Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock worth $359,738,000 after purchasing an additional 607,800 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Teva Pharmaceutical Industries by 7.1% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after purchasing an additional 2,188,212 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 6.9% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock worth $301,920,000 after purchasing an additional 1,860,000 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 9,815 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total value of $128,772.80. Following the completion of the sale, the vice president now owns 9,701 shares in the company, valued at approximately $127,277.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 9,815 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the sale, the vice president now directly owns 9,701 shares of the company’s stock, valued at approximately $127,277.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock worth $5,132,766 in the last quarter. 0.62% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.